Payment overview · 2025
General Payments
$275.18
5 reported records · 4 companies
Healthcare provider profile · identity verified
Edwin B. Antommattei, MD
Allopathic & Osteopathic Physicians|General Practice · SABANA GRANDE, PR · NPI 1841261443
Verified facts
What the public records show
CMS Open Payments records show Edwin B. Antommattei, MD received $275.18 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.87 | 49.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.03 | 32.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.74 | 11.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.54 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $275.18 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $136.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 521 | 122 |
| Losartan Potassium | Losartan Potassium | 474 | 119 |
| Simvastatin | Simvastatin | 463 | 119 |
| Metformin Hcl | Metformin Hcl | 405 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 102 |
| Famotidine | Famotidine | 318 | 65 |
| Lisinopril | Lisinopril | 314 | 66 |
| Glimepiride | Glimepiride | 285 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 63 |
| Gabapentin | Gabapentin | 226 | 56 |
| Omeprazole | Omeprazole | 216 | 35 |
| Synthroid | Levothyroxine Sodium | 195 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 142 | 36 |
| Alendronate Sodium | Alendronate Sodium | 134 | 37 |
| Lansoprazole | Lansoprazole | 134 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 32 |
| Furosemide | Furosemide | 119 | 32 |
| Finasteride | Finasteride | 114 | 22 |
| Carvedilol | Carvedilol | 108 | 27 |
| Azithromycin | Azithromycin | 100 | 86 |
| Latanoprost | Latanoprost | 98 | 16 |
| Levofloxacin | Levofloxacin | 95 | 78 |
| Temazepam | Temazepam | 95 | 14 |
| Trazodone Hcl | Trazodone Hcl | 92 | 17 |
| Memantine Hcl | Memantine Hcl | 88 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 23 |
| Farxiga | Dapagliflozin Propanediol | 86 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 86 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 20 |
| Irbesartan | Irbesartan | 78 | 18 |
| Sertraline Hcl | Sertraline Hcl | 76 | 17 |
| Allopurinol | Allopurinol | 73 | 16 |
| Donepezil Hcl | Donepezil Hcl | 73 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 20 |
| Clonazepam | Clonazepam | 71 | 12 |
| Meloxicam | Meloxicam | 69 | 57 |
| Ezetimibe | Ezetimibe | 68 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 14 |
| Enalapril Maleate | Enalapril Maleate | 65 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Spironolactone | Spironolactone | 62 | 12 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Methotrexate | Methotrexate Sodium | 61 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 60 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 11 |
| Alprazolam | Alprazolam | 59 | suppressed |
| Dexamethasone | Dexamethasone | 57 | 45 |
| Mirtazapine | Mirtazapine | 57 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 45 | suppressed |
| Prednisone | Prednisone | 44 | 22 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 14 |
| Fluconazole | Fluconazole | 42 | 35 |
| Levo-T | Levothyroxine Sodium | 42 | 17 |
| Cefadroxil | Cefadroxil | 41 | 39 |
| Cilostazol | Cilostazol | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 31 |
| Glipizide | Glipizide | 40 | 12 |
| Insulin Lispro | Insulin Lispro | 40 | suppressed |
| Risperidone | Risperidone | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Etodolac | Etodolac | 37 | 29 |
| Tramadol Hcl | Tramadol Hcl | 36 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | 12 |
| Ketoconazole | Ketoconazole | 31 | 11 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 31 | 26 |
| Atenolol | Atenolol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Naproxen | Naproxen | 30 | 25 |
| Celecoxib | Celecoxib | 29 | 22 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 23 | 15 |
| Primidone | Primidone | 23 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 15 |
| Metronidazole | Metronidazole | 18 | 17 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Advocate Syringes | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | 12 |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | 12 |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Methscopolamine Bromide | Methscopolamine Bromide | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Desonide | Desonide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $275.18 · 5 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, JARDIANCE, MOUNJARO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error